At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Alternating Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma: A Phase II Study of Alternating Sunitinib and Temsirolimus
In Brief
A Phase 2 clinical trial evaluating Sunitinib and Temsirolimus for Metastatic Renal Cell Carcinoma. Completed, enrolled 37 participants across 2 sites.
Detailed Summary
In the past 5 years, treatment for metastatic Renal Cell Carcinoma (mRCC) has focused on agents directed at blocking tumor and vascular growth pathways. Sunitinib blocks the vascular endothelial growth factor receptor (VEGFr) and temsirolimus is an inhibitor of mammalian target of rapamycin (mTOR). Both sunitinib and temsirolimus are FDA approved agents for mRCC. When agents like these are given together, the toxicity increases but they can be given safely, at full doses, sequentially. We hypothesize that alternating these agents will double the progression free survival (PFS) of the agents when given sequentially.
Study Details
Timeline
Interventions
Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest
Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest